Skip to content
CancerIndex

Loading the knowledge graph…

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC — knowledge graph · CancerIndex